A study of ICP-332 for moderate to severe plaque psoriasis
Treatments studied
Part of Skin clinical trials.
This trial tests an oral medication called ICP-332 versus a placebo (a pill with no active drug) for people with moderate to severe plaque psoriasis. The goal is to see if ICP-332 can improve skin symptoms and be safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have had plaque psoriasis for at least 6 months.
- Your psoriasis is moderate to severe (covering 10% or more of your body, and you need or have been offered systemic treatment or light therapy).
- You do not have other types of psoriasis (like guttate, inverse, or pustular).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This trial tests an experimental pill called D-2570 for people with moderate to severe plaque psoriasis. It aims to see if the pill can safely improve skin symptoms like redness, scaling, and thickness.
This study tests an oral medication (HSK47388) as a treatment for moderate-to-severe plaque psoriasis, the most common type. It may help reduce symptoms like red, scaly patches and improve quality of life.
This study tests an investigational drug called SHR-1139 for people with moderate-to-severe plaque psoriasis who have not responded well to previous biologic treatments. The goal is to see if it can reduce psoriasis symptoms safely.
This trial tests an oral medication called piclidenoson for people with moderate-to-severe plaque psoriasis. It aims to see how safe and effective it is compared to a placebo.
This trial tests a new study drug called HSK44459 for people with moderate to severe plaque psoriasis. The hope is that the drug can reduce psoriasis symptoms and improve quality of life. Participation involves receiving the study drug and being monitored for safety and effectiveness.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.